Assessing the role of Anti-Müllerian hormone in women's reproductive health
Official title: Clinical Application of Serum Anti-Müllerian Hormone (AMH) Measurements
Run by Chinese University of Hong Kong · NCT05858307 · Data updated 2026-11-12
This study is testing if measuring a hormone called Anti-Müllerian hormone (AMH) can help women with conditions like polycystic ovarian syndrome and premature ovarian insufficiency, and improve their chances of success with fertility treatments.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 10 Years to 44 Years |
| Sex | Women only |
| Enrollment | 300 (estimated) |
| Sponsor | Chinese University of Hong Kong Academic / other |
| Locations | 1 site (Hong Kong) |
| Status | Recruiting |
| Started | June 22, 2022 |
| Main results expected | June 30, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | March 27, 2025 |
| Trial ID | NCT05858307 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include women attending clinics for the management of PCOS and POI, as well as those seeking ART treatment.
✕Probably not a fit
Patients outside the age range of 10 to 45 years or those with conditions affecting hormone secretion may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study evaluates the association of serum Anti-Müllerian hormone (AMH) levels with conditions such as polycystic ovarian syndrome (PCOS) and premature ovarian insufficiency (POI), as well as its predictive value in assisted reproductive technology (ART) outcomes. The study aims to determine the utility of AMH in diagnosing PCOS, managing POI, and optimizing gonadotropin regimens for ovarian stimulation in ART. By analyzing AMH levels alongside other reproductive markers, the research seeks to enhance understanding of ovarian function and improve reproductive outcomes for women undergoing ART.
Why it matters
Potential benefit: If successful, this study could provide a reliable biomarker for diagnosing and managing reproductive health issues in women, potentially improving fertility outcomes.
How similar studies have gone: Previous studies have shown promising results in using AMH as a marker for reproductive health, indicating potential success for this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Women attending the Paediatric and Adolescent Gynaecological Clinic and Gynaecological Endocrine Clinic of in the Department of Obstetrics and Gynaecology at the Prince of Wales Hospital for the management of PCOS and POI * Women attending the Assisted Reproductive Technology (ART) Unit of The Chinese University of Hong Kong for ART treatment Exclusion Criteria: * Women with age \<10 or ≥45 * Current or past diseases affecting gonadotropin, sex steroid secretion, clearance and excretion
Where it's running
-
The Chinese University of Hong Kong
Hong Kong, Hong Kong Recruiting
Study contacts
- Principal investigator: Pui Wah Jacqueline Chung — Chinese University of Hong Kong
- Study coordinator: Wing Iu Li
- Email: wingiuli@cuhk.edu.hk
- Phone: +852 35051764
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Autologous Hair Follicle Secretome + PRP for POI
This pilot study tests whether a patient’s own hair follicle secretome combined with their own platelet-rich plasma can improve ovarian function in women with premature ovarian insufficiency.
-
Intravenous hUC-MSCs for POI: Safety, Tolerability and Early Efficacy
We’re testing whether IV human umbilical cord mesenchymal stem cells can be safely given to women under 40 with premature ovarian insufficiency to see if it helps improve ovarian function.
-
Neurodynamic Stretch vs Myofascial Pain Release for PCOS-Related Dysmenorrhea
This trial tests whether neurodynamic stretching with diaphragmatic breathing or myofascial pain release can help reduce cramps and improve sleep in young women with PCOS.
-
Human amniotic mesenchymal stem cell treatment for premature ovarian insufficiency
This trial will test whether an intravenous infusion of human amniotic mesenchymal stem cells combined with standard hormone therapy can help women under 40 with premature ovarian insufficiency.
-
FRAME support for women undergoing fertility care
This pilot will test whether giving women access to the FRAME app and an external support team for six months reduces stress and improves emotional well-being during fertility care.
-
Constant 5% versus sequential 5% to 2% oxygen for embryo culture in IVF
This will test whether keeping embryos at a constant 5% oxygen level or lowering oxygen from 5% to 2% during culture changes term live birth rates for women undergoing blastocyst IVF.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.